Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +748.31%
#3 ADO Protocol ADO Protocol +100.35%
#4 Cortex Cortex +92.23%
#5 Ontology Gas Ontology Gas +81.46%
#6 Kinesis Silver Kinesis Silver +54.18%
#7 OpenEden OpenEden +32.01%
#8 Biconomy Biconomy +28.78%
#9 Magma Finance Magma Finance +25.15%
#10 QuantixAI QuantixAI +23.21%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX
Classifica tra le azioni #4213
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Prezzo delle azioni
$34.45
Capitalizzazione di mercato
$4.02B
Variazione (1 giorno)
0.83%
Variazione (1 anno)
32.31%
Paese
US
Scambia Viking Therapeutics, Inc. (VKTX)

Categoria

Healthcare
Ricavi di Viking Therapeutics, Inc. (VKTX)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Viking Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Viking Therapeutics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH